anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the population suffering from cancer, children and teenagers are in the majority. For children with rapid development of body and mind, with the change of cognitive ability, they will feel anxiety and fear about the expected potential negative events. Painting art therapy is a kind of non-verbal psychological therapy through the interaction between the painter, the painting work and the therapist, with the painting creation activity as the intermediary. The purpose is to develop symbolic language, touch the inner subconscious, and integrate into the personality, so as to produce cognitive and behavioral changes. Painting therapy and psychological analysis can improve the treatment compliance of children bone tumor patients, make psychological nursing and health education of patients more targeted, and promote the cooperation between medical care and patients. Forty pediatric bone tumor patients meeting the requirements were selected from the bone and soft tissue ward of our hospital. Twenty subjects were randomly divided into experimental group and control group. The experimental group underwent psychological evaluation, drawing analysis and psychotherapy intervention before and after chemotherapy and surgery, while the control group only underwent psychological evaluation without drawing analysis and psychotherapy intervention. This experiment was designed to evaluate the change of psychological state of children after intervention. To verify whether the intervention has improved the psychological and cognitive aspects of the children.
1404225 Active material obtained from parathyroid CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT 4 Aug 1972 [4 Aug 1971] 36608/72 Heading A5B A water-soluble hormone-like substance having a M.W. between 200 and 500 and physiological effects including increasing the blood level of Si, Zn, Cu and Mn, causing phosphaturia and alleviating rhino-larings-pharingitis sieca, is obtained by extracting with water mammalian parathyroid tissue (including cell cultures thereof) which may first be dried, ground and, optionally, defatted e.g. by treatment with acetone. The product may be concentrated by conventional means e.g. chromatography, dialysis, gel filtration &c., unwanted protein being removed by precipitation e.g. with trichloracetic or sulphosalicylic acid. The active material may be incorporated into pharmaceutical and cosmetic compositions with conventional carriers and excipients. (From GB1404225 A) [FR2150719A1]
Parkinson's disease (also known as Parkinson's, Parkinson disease, or PD) is a degenerative disorder of the central nervous system that impairs motor skills, cognitive processes, and other functions. The most obvious symptoms are motor-related, including tremor, rigidity, slowness of movement, and postural instability. Among non-motor symptoms are autonomic dysfunction and sensory and sleep difficulties. Cognitive and neurobehavioral problems, including dementia, are common in the advanced stages of the disease. PD usually appears around the age of 60, although there are young-onset cases.

Gaucher's disease is a genetic disease in which a fatty substance (lipid) accumulates in cells and certain organs. Gaucher's disease is the most common of the lysosomal storage diseases. It is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as acid β-glucosidase). The enzyme acts on a fatty substance glucocerebroside (also known as glucosylceramide). When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain and bone marrow.

Symptoms of Parkinson's syndrome in classical type 1 Gaucher patients were first systematically described in 1996. In GD patients, a marked heterogeneity is detected in terms of disease-causing mutations. In 17 Gaucher patients with symptoms of Parkinson's disease, 12 different genotypes were sequenced and compared to other Parkinson's patients, a lower L-dopa responsiveness, a higher frequency of cortical dysfunction and a relatively early onset of the symptoms was described. Many of these Gaucher patients with clinical Parkinson's symptoms had a positive family history of Parkinson's disease among relatives with heterozygous mutations in the Gaucher gene that could be confirmed in systematic studies.
PCT No. PCT/EP97/02510 Sec. 371 Date Feb. 8, 1999 Sec. 102(e) Date Feb. 8, 1999 PCT Filed May 15, 1997 PCT Pub. No. WO97/43362 PCT Pub. Date Nov. 20, 1997The present invention relates to a process of treating an oil, the process comprising contacting the oil with a polar solvent to extract at least one compound that is soluble in the solvent, and then separating the solvent containing the compound from the so treated oil. The oil is microbially derived, and extracted either from a fermentation broth or a filtrate thereof using hexane. The compound to be extracted is usually a sterol or a diglyceride. The solvent is ethanol having up to 5% water. The oil can contain a polyunsaturated fatty acid such as C18, C20 or C22  omega -3 or  omega -6 fatty acid, such as arachidonic acid.
PURPOSE:To obtain the titled anti-inflammatory agent having low side effect and toxicity, by using mucilage exuded from the surface gland of leaf of dew grass (Drosea ratundifolia L) as an active component. CONSTITUTION:Mucilage exuded from the surface land of the leaf of dew grass is used as an active component of the objective agent. The mucilage-containing material is e.g. decocted leaf, whole grass, etc., extract of leaf, whole grass, etc., (e.g. water-extracted component) or their dried product, especially dried powder, etc. It can be used as an anti-inflammatory agent for mammals such as man, dog, horse, rat, etc. It is administered e.g. by applying as an external drug (e.g. ointment, poultice, solution, etc.) and the does is preferably 0.1-20mg/cm<2> per does as a freeze-dried mucilage. It has excellent anti- inflammatory effect and is free from side effect appearing in steroid drug.
Non-cystic fibrosis bronchiectasis is an orphan disease caused by the pathogenic vicious circle including infection, inflammation and airway repair. Today's principle of treatment is to break the cycle of inflammation and infection. Nowadays, most clinical trials are anti-infective treatment by antibiotics trying to break this cycle by reducing the bacterial load, which may cause bacterial resistance. There were still some anti-inflammation trials by using inhaled corticosteroids(ICS). Tsang and Martínez-García showed that inhaled corticosteroids reduced IL-1,IL-8 levels and sputum inflammation cells, and improved sputum volume as well as quality of life, though the corticosteroid must be high dose or medium dose combined with long-acting ß2 adrenergic agonists. As described in asthma and chronic obstructive pulmonary disease(COPD), theophylline can improve the activity of histone deacetylase (HDAC) and then enhanced the anti-inflammatory effect of steroids. We hypothesis that theophylline may have the same effect in subjects with bronchiectasis. Theophylline plus inhaled low-dose formoterol-budesonide may improve quality of life and reduce airway inflammation.
PURPOSE: A novel method for manufacturing fermented ginseng or fermented red ginseng using yeast is provided to reduce reaction time and to remarkably enhance ginsenoside compound K content. CONSTITUTION: A method for manufacturing fermented ginseng or fermented red ginseng, which enhances ginsenoside compound K content comprises a step of adding Pichia pastoris yeast to ginseng or red ginseng and fermenting. The yeast is immobilized using alginate or a PVA(polyvinyl alcohol)-alginate mixture, or is not immobilized. The ginseng includes Panax ginseng, P. quiquefolius, P. notoginseng, P. japonicas, P. trifolium, P. pseudoginseng, or P. vietnamensis. The yeast includes Pichia anomola, Pichia anomola, Pichia guilliermondii, Pichia kluyveri, Pichia membranifaciens, Pichia norvegensis, Pichia ohmeri, Pichia pastoris or Pichia subpelliculosa. [Reference numerals] (AA) Before fermentation; (BB) 1 day after fermentation
This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
PURPOSE:To obtain the titled active substance from a specific proteinic subunit substance and a proteinic modifying subunit substance. CONSTITUTION:A mixed active substance (IAP) for enhancing the secretion of insulin obtained from at least one of a proteinic subunit, e.g. Ps-1, P-3, P-4 or Ps- 5, constituting an active substance for enhancing the secretion of insulin produced by a microorganism of the genus Bordetella and a proteinic modifying subunit substance which is a modifier of a given proteinic subunit substance. The above-mentioned subunit substance is obtained by reacting an active substance for enhancing the secretion of insulin produced by a microorganism of the genus Bordetella with an amidination agent of the formula (R1 is H, 1-4C lower alkyl or chloromethyl, etc.; R2 is 1-4C lower alkyl), and macerating the resultant compound. The above-mentioned mixed IAP has weakened leukocytotic action though with an effective pharmacological activity almost the same as that of the unmodified IAP.
Noncoding and coding RNAs are key regulators of plant growth, development, and stress responses. To investigate the types of transcripts accumulated during the vegetative to reproductive transition and floral development in the Coffea arabica L., we sequenced small RNA libraries from eight developmental stages, up to anthesis. We combined these data with messenger RNA and PARE sequencing of two important development stages that marks the transition of an apparent latent to a rapid growth stage. In addition, we took advantage of multiple in silico tools to characterize genomic loci producing small RNAs such as phasiRNAs, miRNAs, and tRFs. Our differential and co-expression analysis showed that some types of small RNAs such as tRNAs, snoRNAs, snRNAs, and phasiRNAs preferentially accumulate in a stage-specific manner. Members of the miR482/miR2118 superfamily and their 21-nucleotide phasiRNAs originating from resistance genes show a robust co-expression pattern that is maintained across all the evaluated developmental stages. Finally, the majority of miRNAs accumulate in a family stage-specific manner, related to modulated hormonal responses and transcription factor expression.
This invention is directed to alkylthiobenzylpiperidine compounds which are ligands at the MCHl receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression comprising administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention further provides a method of treating a subject suffering from anxiety comprising administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity comprising administering to the subject a therapeutically effective amount of a compound of the subject invention. Furthermore, the present invention is directed to the use of a compound of the subject invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.
Premature Closure of Fetal Ductus Arteriosus:

Avoid use of NSAIDs, including DUEXIS, in pregnant women at about 30 weeks gestation and later. NSAIDs, including DUEXIS, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment:

Use of NSAIDs, including DUEXIS, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit DUEXIS use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if DUEXIS treatment is needed for a pregnant woman. Discontinue DUEXIS if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
A multi-mode system and method for exchanging patient medical record information and data an order for a medical procedure for a patient between different medical information systems for producing medical report data is provided. The system comprises a repository including a first set of clinical data items employing a first set of codes, terms and identifiers associated with a plurality of different patients accessible by a parent medical information system application. A user interface initiates generation of data representing at least one display image. The at least one display image includes a first image element for, in a first mode of operation, initiating execution of the parent medical information system application and enabling access to the plurality of data items in the repository. The display window further includes a second image element for, in a second mode of operation, initiating execution of a child medical information system application for processing a second set of clinical data items employing a second different set of codes, terms and identifiers. A mapping processor adaptively switches from using the first set of codes terms and identifiers in the first mode to using of the second set of codes, terms and identifiers in the second mode and employs a map associating the first set of codes, terms and identifiers with the second set of codes, terms and identifiers in response to configuration data enabling the child medical system application to access data stored in the repository, in response to user selection of the second image element. A data interface is conditioned for using said map in automatically transferring a value of a selected individual data item from said repository to a data field employed by said child medical information system application when operating in said second mode for outputting medical report data.
Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.
The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
Nocebo hyperalgesia is a pervasive problem in which the treatment context triggers negative expectations that exacerbate pain. Thus, developing ethical strategies to mitigate nocebo hyperalgesia is crucial. Emerging research suggests that choice has the capacity to reduce nocebo side effects, but choice effects on nocebo hyperalgesia have not been explored. This study investigated the impact of choice on conditioned nocebo hyperalgesia using a well-established electrocutaneous pain paradigm where increases in noxious stimulation were surreptitiously paired with the activation of a sham device. In study 1, healthy volunteers (N = 104) were randomised to choice over (nocebo) treatment administration, nocebo administration without choice, or a natural history control group. Nocebo hyperalgesia was greater for those with choice than no choice, suggesting that choice increased rather than diminished nocebo hyperalgesia. Study 2 tested whether providing positive information about the benefits of choice in coping with pain could counteract heightened nocebo hyperalgesia caused by choice. A different sample of healthy adults (N = 137) were randomised to receive nocebo treatment with choice and positive choice information, choice only, or no choice. The positive choice information failed to attenuate the effect of choice on nocebo hyperalgesia. The current results suggest that, rather than decreasing nocebo hyperalgesia, treatment choice may exacerbate pain outcomes when a painful procedure is repeatedly administered. As such, using choice as a strategy to mitigate nocebo outcomes should be treated with caution.
Chromothripsis is a frequent form of genome instability, whereby a presumably single catastrophic event generates extensive genomic rearrangements of one or multiple chromosome(s). However, little is known about the heterogeneity of chromothripsis across different clones from the same tumour, as well as changes in response to treatment. Here we analyse single-cell genomic and transcriptomic alterations linked with chromothripsis in human p53-deficient medulloblastoma and neural stem cells (n = 9). We reconstruct the order of somatic events, identify early alterations likely linked to chromothripsis and depict the contribution of chromothripsis to malignancy. We characterise subclonal variation of chromothripsis and its effects on extrachromosomal circular DNA, cancer drivers and putatively druggable targets. Furthermore, we highlight the causative role and the fitness consequences of specific rearrangements in neural progenitors.
Endocrine therapy is an established treatment for hormone receptor-positive breast cancer, but can cause significant side effects with deterioration in quality of life. The side effects of all forms of endocrine therapy are well recognized and can lead to treatment non-persistence or non-compliance. Compliance is defined as the degree or extent of conformity to the recommended administration by the provider, whereas persistence refers to the act of continuing treatment for a certain prescribed duration. Treatment adherence is especially important in breast cancer, as early cessation or reduced compliance to hormonal therapy are associated with reduced disease-free survival and increased mortality. Chronotherapy, also called chronotherapeutics, is defined as the administration of a medication in coordination with circadian rhythm in order to minimize side effects and yield a greater efficacy. The investigators propose to perform a pragmatic, multi-centre, open-label, randomized clinical trial to establish the optimal timing (morning vs. evening) of administering endocrine therapy based on side effects and benefits in early stage breast cancer patients.
Although it is believed that myopia is the result of an interplay between genetic and environmental factors and its progression has been attributed to the lack of outdoor activities and intensive school work, myopia control methods mainly focus on optical and pharmaceutical interventions. Use of bifocal and multifocal lenses have been shown to be ineffective in myopia control. Specially designed soft contact lenses for myopia control have recently been launched, but their effectiveness has yet to be confirmed. Currently, overnight-wear orthokeratology (ortho-k), which involves reshaping the cornea by overnight wear allowing for improved, frequently unaided, vision during the day, is used extensively in Hong Kong. Approximately 50% retardation in axial length elongation was observed in studies of patients receiving ortho-k (LORIC study, 46%, ROMIO study,43%, and TO-SEE study, 52%).

Pharmaceutical methods have focused on the use of atropine eye drops to slow myopic progression. The use of 1% atropine was first suggested in the 1990's, but its application was limited by the manifestation of side effects such as pupil dilatation and loss of accommodation. The effectiveness of lower concentrations (0.5%, 0.1% and 0.01%) have been evaluated in a recent five-year randomized clinical trial, where the authors reported that 0.01% atropine once daily was effective resulting in about 50% of spherical equivalent reduction. However, this was as a result of one year (3rd year) discontinuation of atropine in the five-year study. Rebound effect was minimal with 0.01% atropine and higher dosages were associated with more manifest rebound effects, which appeared to negate former myopia retardation effects. Only 24% of those receiving 0.01% progressed 0.50D or more after discontinuation for one year. By contrast, proportion of children progressed 0.50D or more in 0.5% and 0.1% groups were 59% and 68% respectively. Moreover, use of 0.01% atropine showed sustained myopia reduction with clinically negligible effects on pupil dilatation and loss of accommodation. The authors suggested the use of 0.01% as the optimum concentration for controlling myopia.

The mechanisms of neither ortho-k nor atropine in myopia control are fully understood. It is believed that ortho-k and atropine act via different mechanisms, with ortho-k slowing myopia progression by reducing peripheral hyperopic defocus, while atropine exerts effects on anti-muscarinic receptors of the retina and sclera. However, some subjects respond poorly to either atropine or ortho-k, as demonstrated in clinical trials, suggesting that a single treatment may be not enough. It is possible that by combining these two methods, additional retardation of myopia progression could be achieved. In this randomized trial, we will explore the effectiveness of combination of ortho-k and atropine therapy, and evaluate additional effects by comparing the combination with ortho-k treatment alone.